Travis Murdoch, HI-Bio CEO
May 24, 2024 07:26 AM EDTUpdated 09:22 AM
R&D

HI-Bio out­lines da­ta that sparked $1.15B Bio­gen buy­out

Max Gelman

Senior Editor

Days af­ter get­ting ac­quired by Bio­gen, Hu­man Im­munol­o­gy Bio­sciences re­vealed Phase 2 da­ta that helped seal the deal.

In the tri­al, which looked at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Up­dat­ed: Telix Phar­ma­ceu­ti­cals pulls Nas­daq list­ing plans just be­fore trad­ing was to start

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Nurix’s pro­tein de­grad­er over­comes re­sis­tance to BTK mu­ta­tions in small leukemia study

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times